Galderma Group AG Registered Shares GALD

Morningstar Rating
CHF 160.80 −5.05 (3.04%)
View Full Chart

Company Report

Galderma's Diversified Dermatology Portfolio and Drug Pipeline Position It Well for Long-Term Growth

Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue growth is supported by changing consumer behavior and perception around skin health and appearance. The firm deploys an omnichannel go-to-market strategy, supported by a specialized, high-touch salesforce of over 2,500 employees reaching around 300,000 healthcare professionals. A leading presence at dermatology congresses complements this, and an emphasis on educational, training, and loyalty programs helps to reinforce physician entrenchment.

Price vs Fair Value

GALD is trading at a LOCK|kTr^hV% premium.
Price
CHF 160.80
Fair Value
&VP
Uncertainty
LOCK|nB!hB
1-Star Price
LOCK|K.p
5-Star Price
>%
Economic Moat
LOCK|@&Pp@
Capital Allocation
LOCK|@<CH^?

Bulls Say, Bears Say

Bulls

Galderma’s sizable innovation pipeline should translate into accelerated revenue growth and EBITDA margin accretion over the midterm.

Bears

The agreement with Ipsen for the current neuromodulator portfolio features stepped royalties that have been weighing on margins and may limit the company in pursuing volume market share growth.

News

Trading Information

Previous Close Price
CHF 165.85
Day Range
CHF 160.60–167.85
52-Week Range
CHF 134.70–188.25
Bid/Ask
CHF 0.00 / CHF 0.00
Shares Outstanding
233.19M
Market Cap
CHF 37.50B
Volume/Avg
987,408 / 537,256

Key Statistics

Price/Earnings (Normalized)
52.37
Price/Sales
8.06
Dividend Yield (Trailing)
0.22%
Dividend Yield (Forward)
0.22%
Dividend Payment Schedule
Apr
Total Yield
0.91%

Company Profile

Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Growth
Total Number of Employees
7,600

Competitors

Valuation

Metric
GALD
BEI
OR
Price/Earnings (Normalized)
52.3712.9729.84
Price/Book Value
5.651.845.85
Price/Sales
8.061.724.39
Price/Cash Flow
39.9414.0922.72
Price/Earnings
GALD
BEI
OR

Financial Strength

Metric
GALD
BEI
OR
Quick Ratio
0.931.500.58
Current Ratio
1.242.000.97
Interest Coverage
6.8442.9719.89
Quick Ratio
GALD
BEI
OR

Profitability

Metric
GALD
BEI
OR
Return on Assets (Normalized)
7.31%7.60%11.46%
Return on Equity (Normalized)
12.07%11.37%20.96%
Return on Invested Capital (Normalized)
10.17%10.80%15.09%
Return on Assets
GALD
BEI
OR

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|wkJ?$$pLOCK|#XthP$66B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|#&KY^?&LOCK|$y@!$46B
Haleon PLC ADR
HLN
LOCK|<LfkCV!LOCK|<J<$38B
Zoetis Inc Class A
ZTS
LOCK|^M>zTnDLOCK|lR<$29B
Viatris Inc
VTRS
LOCK|ZkBTbdyLOCK|fLs$20B
Elanco Animal Health Inc
ELAN
LOCK|&GDLOCK|Cls$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|D%$gXdLOCK|Yl%$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|Bsp!yrLOCK|FY>$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|>%?C@HLOCK|v@Zvg$2B
Perrigo Co PLC
PRGO
LOCK|<WkB@<PLOCK|HpH$2B

Sponsor Center